- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3% - What's Next? | 1 | MarketBeat | ||
| 05.09. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences | 1 | GlobeNewswire (USA) | ||
| 29.08. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit | 1 | GlobeNewswire (USA) | ||
| 16.08. | Stifel reiterates buy rating on Rapport Therapeutics shares, keeps $35 PT | 1 | Investing.com | ||
| 08.08. | Rapport Therapeutics GAAP EPS of -$1.70 misses by $1.02 | 1 | Seeking Alpha | ||
| 08.08. | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Rapport Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present Data for TARPy8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain | 1 | GlobeNewswire (USA) | ||
| 05.07. | Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More | 19 | Insider Monkey | ||
| 12.06. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement | 116 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small... ► Artikel lesen | |
| 10.06. | Rapport Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.06. | A good rapport: Rapport Therapeutics rises 22% in IPO, reopening the door for biotech listings | 2 | Renaissance Capital | ||
| 07.06. | Rapport Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 07.06. | J&J-backed Rapport Therapeutics valued at $636.8 million after shares rise 6% in debut | 4 | Reuters | ||
| 07.06. | CNS disorder biotech Rapport Therapeutics prices IPO at $17 midpoint | 1 | Renaissance Capital | ||
| 07.06. | Rapport Therapeutics Prices 8M Share IPO at $17/sh | 4 | Investing.com | ||
| 07.06. | J&J-backed Rapport Therapeutics prices IPO at $17 per share | 7 | Seeking Alpha | ||
| 07.06. | J&J-backed Rapport Therapeutics raises $136 million in US IPO | 5 | Reuters | ||
| 07.06. | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Pricing of Initial Public Offering | 134 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small... ► Artikel lesen | |
| 04.06. | Rapport Therapeutics, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,540 | -1,20 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen auf "Kaufen" mit einem fairen Wert von 50 Euro belassen. Der Labordienstleister und Diagnostikspezialist verfüge u?ber ein ausgezeichnetes... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,17 | 0,00 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| DYNE THERAPEUTICS | 34,730 | 0,00 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 37,070 | -1,38 % | Tarsus taps actor Betsy Sodaro to embody a 'mitey problem' in 1st Xdemvy DTC TV ad | ||
| NUVALENT | 102,16 | -2,53 % | NUVL: CEO Porter James Richard verkauft Aktien und übt Optionen aus | ||
| NURIX THERAPEUTICS | 24,720 | -4,22 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update | Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom's... ► Artikel lesen | |
| EVOTEC | 5,570 | +3,05 % | Noch 26 Tage: Evotec vor Übernahme-Überraschung? | Nur noch 26 Tage bis zum Showdown: Gelingt es Evotec (WKN: 566480), im Rahmen seiner 9-Monats-Zahlen ein neues Kursfeuerwerk zu entfachen? Die Chancen stehen gut. Eine unlängst veröffentlichte Unternehmenspräsentation... ► Artikel lesen | |
| JANUX THERAPEUTICS | 49,810 | 0,00 % | Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,580 | 0,00 % | Summit Therapeutics (NASDAQ:SMMT) Trading Down 5% - Should You Sell? | ||
| HARMONY BIOSCIENCES | 34,970 | 0,00 % | Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028 | WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK)... ► Artikel lesen | |
| HUMACYTE | 4,820 | 0,00 % | Humacyte, Inc: Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 | DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 16,130 | 0,00 % | Kathleen D. Scott Sells 12,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock | ||
| ARCTURUS THERAPEUTICS | 20,600 | 0,00 % | Pad Chivukula Sells 12,000 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock | ||
| DAY ONE BIOPHARMACEUTICALS | 15,080 | +0,47 % | Day One Biopharmaceuticals, Inc.: Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 | ||
| ADMA BIOLOGICS | 16,135 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang |
RAPPORT THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 28,050 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.
